Clinical trial register · Spain

Clinical Trials in Málaga, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Málaga

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Jaén, Málaga, Palma de Mallorca, Salamanca, Barcelona, L'Hospitalet de Llobregat, Valencia, A Coruña

2027-11-23

Not yet open

A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT)

NCT07839676Borderline and Locally Advanced Pancreatic Cancer

Fernando Pessoa Canarias University

Not applicable

Las Palmas de Gran Canaria, Málaga

2027-03-31

Not yet open

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562Systemic Sclerosis

DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

A Coruña, Barcelona, Málaga

2027-02-03

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Santander, Santiago de Compostela, Barcelona, Coslada, Girona, Madrid, Málaga, Oviedo

2026-12-16

Not yet open

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

NCT07789015Idiopathic Inflammatory Myopathies

DrugNerandomilast

Boehringer Ingelheim

Phase 3

270

Barcelona, Madrid, Málaga, Valencia

2026-11-09

Not yet open

Sarcopenia Screening in Advanced Coxarthrosis: The SARCO-COX Study

NCT07734129Sarcopenia, Coxarthrosis

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

150

Málaga

2026-11-01

Not yet open

Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

NCT07862946Acute Lymphobkastic Leukemia, Adult

DrugInotuzumab Ozogamicin

PETHEMA Foundation

Phase 2

Seville, Valencia, Badalona, Barcelona, Madrid, Málaga, Salamanca, San Sebastián

2026-10-30

Recruiting

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases

DrugZenpep

Aimmune Nestlé Health Science US R&D, LLC

Phase 2

Madrid, Murcia, Lleida, Málaga, Valencia

2026-10

Recruiting

neoAGORA: Exploring Clinical Utility of Serial Liquid Biopsy (ctDNA) in Patients With Early-Stage Breast Cancer

NCT07718841Early Breast Cancer (EBC)

Spanish Breast Cancer Research Group

Observational

300

San Sebastián, Barcelona, Madrid, Málaga, Seville, Toledo, Valencia

2026-09-30

Not yet open

Thumb Muscle Activation During Different Activities of Daily Living in Thumb Base Osteoarthritis and Healthy Controls

NCT07866703Trapeziometacarpal Osteoarthritis

University of Malaga

Observational

Málaga

2026-09-26

Recruiting

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer

DrugsPatritumab deruxtecan·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1/2

220

Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife

2026-09-17

Not yet open

Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT07684248Type 1 Diabetes

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

200

Málaga

2026-09-15

Recruiting

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193Colorectal Adenocarcinoma

DrugsVVD-133214·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 2

140

Santiago de Compostela, Barcelona, Madrid, Málaga, Valencia

2026-09-11

Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsImzokitug·Pumitamig·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2

160

Badalona, Seville, Barcelona, Madrid, Majadahonda, Málaga

2026-09-10

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Salamanca, Valencia

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Alicante, Barcelona, Bilbao, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga

2026-09-08

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

Majadahonda, Seville, A Coruña, Jaén, Jerez de la Frontera, Madrid, Málaga, Valencia

2026-09-08

Not yet open

Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma

NCT07763171Gastroesophageal Adenocarcinoma

DrugsRamucirumab·Folfox·Tislelizumab·Paclitaxel

Gruppo Oncologico del Nord-Ovest

Phase 3

244

Barcelona, Madrid, Málaga, Ourense, Pamplona, Santander, Valencia, Zaragoza

2026-09-01

Not yet open

Foot and Ankle Strengthening Program to Improve Physical Function in Menopausal Women (FAMEX)

NCT07472205Menopause, Musculoskeletal Function, Physical Function

University of Malaga

Not applicable

Málaga

2026-09-01

Not yet open

A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

NCT07522801LAL

DrugsEnrylaze·Tofacitinib·Azacitidine·Venetoclax

Philippe ROUSSELOT

Phase 2

Barcelona, Madrid, Málaga, Murcia, Salamanca, San Sebastián, Santander, Seville

2026-09-01

Not yet open

Effects of Virtual Assistant Features on User Experience in Service Settings

NCT07666295User Experience With Virtual Assistants in Service Settings

University of Malaga

Not applicable

400

Málaga

2026-09

Not yet open

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 3

150

Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz

2026-09

Not yet open

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336Diabetes Mellitus, Type 2

DrugsDulaglutide·Orforglipron

Eli Lilly and Company

Phase 3

170

Barcelona, Málaga, Seville

2026-09

Not yet open

Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy

NCT07571954Acute Ischemic Stroke

iVascular S.L.U.

Not applicable

Málaga, Zaragoza, Barcelona, L'Hospitalet de Llobregat, Vigo

2026-08-31

Not yet open

Telerehabilitation in Pulmonary Arterial Hypertension

NCT07799675Pulmonary Arterial Hypertension (PAH)

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2026-08-30

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Seville

2026-08-26

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Badajoz, Barcelona, Burgos, Córdoba, Granada, Madrid, Majadahonda, Málaga

2026-08-21

Recruiting

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

NCT07460986Soft Tissue Sarcoma (STS)

DrugsBexmarilimab·Doxorubicin

MedSIR

Phase 1/2

278

Badalona, Barakaldo, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Zaragoza

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

A Coruña, Alzira, Barcelona, Ferrol, Lleida, Málaga, Oviedo, Segovia

2026-08-20

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

A Coruña, Barcelona, Las Palmas, Madrid, Málaga, Valencia

2026-08-05

Recruiting

Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

NCT07864207Small Cell Lung Cancer ( SCLC )

DrugIDP-121

IDP Discovery Pharma S.L.

Phase 1/2

Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia

2026-07-28

Not yet open

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

NCT07578337Untreated, Advanced Pancreatic Cancer

DrugsNLM-001·Botensilimab·Abraxane·Nab-paclitaxel

Nelum Corp

Phase 2

Zaragoza, Barcelona, Santander, San Sebastián, Santiago de Compostela, Málaga

2026-07-15

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444Rett Syndrome

DrugFintepla

UCB BIOSCIENCES, Inc.

Phase 3

200

Madrid, Málaga, Seville

2026-07-14

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia

2026-07-10

Recruiting

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

NCT07683065Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease

Novartis Pharmaceuticals

Observational

150

Badalona, Barcelona, Madrid, Málaga

2026-07-08

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Barcelona, Ferrol, Lleida, Madrid, Majadahonda, Málaga, Santander, Seville

2026-07-06

Recruiting

Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes

NCT07667504Type 1 Diabetes (T1D), Obesity & Overweight

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2026-07-02

Recruiting

Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

NCT07478991Acute Myeloid Leukemia, Adult

DrugsQuizartinib·Azacitidine·Venetoclax

PETHEMA Foundation

Phase 3

376

Santiago de Compostela, Hospitalet Del Llobregat, Terrassa, Jaén, Alcalá de Henares, San Sebastián de los Reyes, Málaga, Barakaldo

2026-07-02

Not yet open

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

NCT07507968Esophagogastric Adenocarcinoma

DrugDurvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

101

Badalona, Barcelona, Granada, Jaén, Málaga, Oviedo, Pamplona, Valencia

2026-07-01

Recruiting

SucroMet Nutritional Intervention Trial

NCT07656298Overweight , Obesity, Glucose Metabolism

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

120

Málaga

2026-07

Recruiting

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

NCT07508787Renal Transplant Failure and Rejection

DrugsSiplizumab·Rabbit anti-thymocyte globulin·Thymoglobulin

Nefro Avillion Clinical Development, LLC

Phase 2

120

Barcelona, Málaga

2026-06-29

Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471Follicular Lymphoma

DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2/3

960

Badalona, Málaga, Barcelona, Madrid, Salamanca

2026-06-22

Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

DrugsEIK1001·Cisplatin/Carboplatin·Nab-paclitaxel·Pemetrexed

Eikon Therapeutics

Phase 2/3

750

Jerez de la Frontera, Castellon, Barcelona, Girona, Málaga

2026-06-15

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2026-06-11

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia

2026-06-11

Recruiting

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

DrugsArsenic Trioxide·ATRA

Quetzal Therapeutics

Phase 3

150

Palma de Mallorca, Badalona, Barcelona, Cáceres, Málaga, Oviedo, Valencia

2026-06-08

Recruiting

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

NCT07401381Hormone Receptor Positive Early Breast Cancer

Rovi Pharmaceuticals Laboratories

Phase 1

120

Alcorcón, Barcelona, Granada, Jaén, León, Lleida, Manresa, Málaga

2026-06-08

Not yet open

Thumb Muscle Activation During First Dorsal Interosseous Activities of Daily Living in Thumb Base Osteoarthritis

NCT07668986Trapeziometacarpal Osteoarthritis

University of Malaga

Observational

Málaga

2026-06-05

Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902Persistent Corneal Epithelial Defect

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

150

A Coruña, Cardona, Badalona, Barcelona, Madrid, Málaga, Seville, Valencia

2026-06-02

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville

2026-06-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07463521Ocular Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

120

Alicante, Barcelona, Madrid, Málaga

2026-05-27

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

EL Palmar (EL Palmar), San Cristóbal de La Laguna, Bilbao, Barcelona, Granada, Jaén, Madrid, Málaga

2026-05-21

Recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414Obesity, Type 2 Diabetes

DrugsCagriSema·Semaglutide

Novo Nordisk A/S

Phase 3

2,500

A Coruña, Antequera, Barcelona, Centelles (Barcelona), Girona, Madrid, Manresa, Málaga

2026-05-21

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Salamanca, Valencia

2026-05-21

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Barcelona, Esplugues de Llobregat, Madrid, Málaga, Murcia, Valencia

2026-05-20

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526Hemophilia A

Hoffmann-La Roche

Phase 3

138

Barcelona, Madrid, Málaga, Seville, Valencia

2026-05-15

Recruiting

Effectiveness of Best Care Practices in Acute Stroke in Conventional Hospitalization (BEST CARE ICTUS_HC)

NCT07627399Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke

University of Malaga

Not applicable

700

Antequera, Marbella, Ronda, Málaga

2026-05-12

Recruiting

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

NCT07286214Polymyalgia Rheumatica

DrugSarilumab

Sanofi

Phase 4

300

Barcelona, A Coruña, Madrid, San Cristóbal de La Laguna, Málaga, Sabadell

2026-05-12

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela

2026-05-04

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Málaga, Badajoz, Madrid, Seville, Valencia

2026-05-04

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

DrugMK-1045

Merck Sharp & Dohme LLC

Phase 1/2

280

Badalona, Málaga, Barcelona, Madrid

2026-05-03

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

360

Barcelona, Madrid, Málaga, Seville, Valencia

2026-04-27

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Málaga, Barcelona, Santander, Madrid, Marbella, Seville, Toledo, Valencia

2026-04-23

Recruiting

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095Small Cell Lung Cancer

DrugsZL-1310·Tarlatamab·Durvalumab

Amgen

Phase 1

160

Málaga, Barcelona, Valencia, Madrid

2026-04-21

Active, closed

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

606

Almería, Barcelona, León, Madrid, Málaga, Pozuelo de Alarcón, Seville

2026-04-21

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-20

Recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500Ovarian Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 3

420

Barcelona, Madrid, Málaga, Vigo

2026-04-17

Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670Diffuse Cutaneous Systemic Sclerosis

Mediar Therapeutics

Phase 2

Barcelona, Córdoba, Málaga, Valencia

2026-04-16

Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311Multiple Myeloma

DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide

GlaxoSmithKline

Phase 2

200

Jerez de la Frontera, Badalona, Córdoba, Gijón, Madrid, Málaga, Salamanca, Vitoria-Gasteiz

2026-04-15

Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630Obesity, Knee Osteoarthritis (OA)

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-13

Active, closed

Virtual Reality Therapy for Wrist and Hand Injury Recovery

NCT07408622Wrist Injuries, Hand and Upper Limb Trauma, Muskuloskeletan Pain

University of Malaga

Not applicable

Málaga

2026-04-01

Active, closed

Cortical Changes After Upper Limb Immobilization Measured by Electroencephalography

NCT07428304Wrist Injury, Hand and Upper Limb Trauma, Muskuloskeletal Diseases

University of Malaga

Observational

Málaga

2026-04-01

Recruiting

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

NCT07195227Hormon Receptor Positive Breast Cancer, Breast Cancer

DrugsCamizestrant·Ribociclib

MedSIR

Phase 2

150

Alicante, Barcelona, Girona, Granada, Jerez de la Frontera, León, Madrid, Málaga

2026-03-24

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Badalona, A Coruña, Ferrol, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville

2026-03-23

Recruiting

ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women

NCT07580846Menopause, Estrogen Deficiency

Margan Biotech

Observational

100

Madrid, Málaga

2026-03-20

Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib

Merck Sharp & Dohme LLC

Phase 3

400

Las Palmas de Gran Canaria, Girona, Majadahonda, Barcelona, Madrid, Málaga, Seville

2026-03-18

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

L'Hospitalet Del Llobregat, Barcelona, Madrid, Valencia, Barakaldo, Málaga, Seville, Zaragoza

2026-03-16

Recruiting

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470Kidney Transplant Rejection

DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus

Sanofi

Phase 2/3

526

Barcelona, L'Hospitalet de Llobregat, Málaga

2026-03-13

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

Barcelona, Santander, Pamplona, Valencia, Madrid, Málaga

2026-03-13

Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510Non-Small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Pembrolizumab

Bristol-Myers Squibb

Phase 3

750

Barcelona, Barakaldo, Jaén, Madrid, Málaga, Murcia

2026-03-12

Recruiting

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

NCT07194382Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

160

Badalona, Granollers, Santander, Barcelona, Madrid, Málaga

2026-03-10

Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Barcelona, Lugo, Madrid, Marbella, Málaga, Pamplona, Salamanca, Seville

2026-03-03

Recruiting

LONG NAGOMI™ PMCF STUDY

NCT07399002Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

1,039

Cabueñes, Ciudad Real, Elche, Huelva, León, Málaga, Pamplona, Santander

2026-02-27

Active, closed

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2

DrugBerobenatide

Pfizer

Phase 3

1,078

Málaga, Barcelona, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia

2026-02-24

Not yet open

Prevention of ANxiety and Depression Over Risk Assessment

NCT07185867Depression, Anxiety, Prevention, m-Health

The Mediterranean Institute for the Advance of Biotechnology and Health Research

Not applicable

2,595

Málaga

2026-02-15

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Horta-Guinardó, Majadahonda, A Coruña, Barcelona, Málaga, Murcia, Palma de Mallorca, Seville

2026-02-13

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

800

Guadalajara, Lleida, Logroño, Madrid, Málaga, Seville

2026-02-10

Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm

DrugsCasdatifan·PF-08634404·Axitinib·Yervoy

Pfizer

Phase 1/2

224

Barcelona, Málaga, Madrid

2026-02-10

Recruiting

Virtual Reality-based Rehabilitation for Traumatic Hand and Wrist Injuries

NCT07633769Wrist Injury, Hand and Upper Limb Trauma, Hand and Forearm Trauma, Muskuloskeletal Diseases

University of Malaga

Not applicable

Málaga

2026-02-01

By invitation

Slow Breathing and Resistance Exercise in Fibromyalgia

NCT07404384Fibromyalgia, Fibromyalgia Syndrome

University of Malaga

Not applicable

159

Málaga

2026-02

Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177Non-small Cell Lung Cancer (NSCLC)

DrugRina-S

Genmab

Phase 2

240

A Coruña, Barcelona, Las Palmas de Gran Canaria, Logroño, Madrid, Málaga, Pamplona, Valencia

2026-01-30

Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer

DrugsSigvotatug vedotin·PF-08634404

Pfizer

Phase 1/2

162

Jaén, Barcelona, Jerez de la Frontera, Madrid, Málaga, Valencia, Cadiz, Granada

2026-01-30

Recruiting

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009Acute Heart Failure (AHF), Heart Failure (for Example, Fluid Overload), Heart Failure Hospitalization

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Not applicable

1,014

Madrid, Barcelona, Córdoba, Girona, Málaga, Murcia, Salamanca, Sant Joan Despí

2026-01-29

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

NCT07359846Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

Barcelona, Málaga, Seville, Zaragoza

2026-01-20

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Barcelona, Burgos, Elche, Jerez de la Frontera, Madrid, Majadahonda, Málaga, Pamplona

2026-01-16

Recruiting

Digitizing and Automating the Diagnostic Psychiatric Assessment Process

NCT07468214Validation Studies, Psychiatric Diagnosis

Irene Lopez Armenteros

Observational

Málaga

2026-01-09

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07284459Idiopathic Pulmonary Fibrosis

Contineum Therapeutics

Phase 2

324

Málaga, Valencia

2026-01-08

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Barcelona, Hospitalet, Madrid, Majadahonda, Málaga, Seville, Valencia

2026-01-02

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Santiago de Compostela, Barcelona, Madrid, Pamplona, Badalona, Elche (alicante), Málaga, Salamanca

2025-12-31

Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

NCT07218523Bowel Cleansing Prior to Clinical Procedures

DrugsPicoprep·Plenvu

Norgine

Phase 3

212

Ferrol, Palma de Mallorca, Sabadell, Madrid, Málaga

2025-12-29

Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569Hidradenitis Suppurativa

Sanofi

Phase 2

144

Bilbao, Barcelona, Seville, Córdoba, Málaga

2025-12-29

Recruiting

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

NCT06975787Lupus Nephritis (LN)

DrugsVonsetamig·Odronextamab

Regeneron Pharmaceuticals

Phase 1

Seville, Pamplona, Madrid, Málaga

2025-12-22

Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis

DrugsEmpasiprubart·Efgartigimod

argenx

Observational

Málaga, Barcelona

2025-12-19

Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

DrugsEmpasiprubart·Efgartigimod

argenx

Phase 2

Málaga, Barcelona

2025-12-19

Active, closed

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850Obesity and Overweight

DrugBerobenatide

Pfizer

Phase 3

3,578

Málaga, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia

2025-12-19

Recruiting

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection

DrugB/F/TAF

Merck Sharp & Dohme LLC

Phase 2/3

570

Madrid, Valencia, Barcelona, Málaga

2025-12-18

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

480

Palma, Barcelona, Málaga, Oviedo, Valencia

2025-12-17

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

1,035

Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2025-12-15

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Barcelona, Málaga, Sabadell, Santiago de Compostela, Valencia

2025-12-15

Recruiting

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery

Ascendis Pharma A/S

Phase 3

186

Barcelona, Madrid, Málaga, Zaragoza

2025-12-12

Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267Breast Cancer, Advanced Solid Tumor

DrugBG-75202

BeOne Medicines

Phase 1

Barcelona, Madrid, Málaga

2025-12-11

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Santiago de Compostela, Málaga, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Madrid, Córdoba, Valencia

2025-12-11

Recruiting

Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women

NCT07308769Anemia, Iron Deficiency Anemia (IDA)

Pharmanutra S.p.a.

Phase 4

146

Barcelona, Málaga, Sant Cugat del Vallès, Zaragoza

2025-12-11

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Santiago de Compostela, Sabadell, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2025-12-10

Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

NCT07007559Breast Cancer, Metastatic

DrugsEvorpacept·Herceptin·Eribulin·Vinorelbine

ALX Oncology Inc.

Phase 2

120

Málaga, Seville, Bilbao, Barcelona, Lleida, Madrid

2025-12-10

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Alava, Badalona, Barcelona, Madrid, Málaga, Oviedo, Palma, Sabadell

2025-12-09

Recruiting

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945Chronic Kidney Disease

DrugDapagliflozin

Boehringer Ingelheim

Phase 3

120

Barcelona, Bilbao, Málaga, Seville

2025-12-09

Recruiting

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

NCT07222488Bladder Cancer, Urinary Bladder Neoplasms

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

Málaga, Madrid

2025-12-09

Recruiting

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07137598Rheumatoid Arthritis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

160

La Corua, Santiago de Compostela, Málaga, Seville

2025-12-05

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

Málaga, Barcelona, Madrid

2025-12-04

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville

2025-12-03

Recruiting

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

NCT07277270Neoplasms

DrugsGSK5764227·Enzalutamide·Fluorouracil·Leucovorin

GlaxoSmithKline

Phase 1

Barcelona, Madrid, Málaga

2025-12-03

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-12-02

Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146Small-cell Lung Cancer

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 3

480

Valencia, Barcelona, Elche, Girona, Jerez de la Frontera, Madrid, Málaga, Pamplona

2025-11-30

Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel

Amgen

Phase 3

750

Málaga, Barcelona, L'Hospitalet de Llobregat, A Coruña, Lugo, Majadahonda, Pamplona, Madrid

2025-11-28

Recruiting

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms

Eli Lilly and Company

Phase 2

204

Barcelona, Madrid, Mataró, Málaga, Reus

2025-11-28

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Palma de Mallorca, Barcelona, Girona, A Coruña, Madrid, Málaga, Pamplona, Valencia

2025-11-28

Recruiting

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174Small Cell Lung Cancer

DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab

AbbVie

Phase 2

180

Málaga, A Coruña, Barcelona, Madrid

2025-11-25

Recruiting

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291Amyotrophic Lateral Sclerosis (ALS)

DrugsCromolyn Sodium·Riluzole

PhenoNet, Inc.

Phase 2

105

Alicante, Barcelona, Madrid, Málaga, Seville

2025-11-25

Recruiting

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

NCT07209462Fragile X Syndrome

Mirum Pharmaceuticals, Inc.

Phase 2

Barcelona, Málaga

2025-11-22

Recruiting

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice

NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes

Outcomes'10

Observational

334

Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia

2025-11-20

Recruiting

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum

Crinetics Pharmaceuticals Inc.

Phase 3

141

Barcelona, Madrid, Málaga, Seville, Valencia

2025-11-19

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-19

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

A Coruña, Barcelona, Córdoba, Granada, Madrid, Málaga, Palma de Mallorca, Santander

2025-11-18

Recruiting

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

NCT06948448Colorectal Cancer

DrugsONO-4578·Leucovorin·Opdivo·Adrucil

Ono Pharmaceutical Co., Ltd.

Phase 2

144

Badalona, Barcelona, Córdoba, Madrid, Seville, Málaga, Valencia

2025-11-18

Recruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

NCT07284342Advanced Parkinson's Disease

AbbVie

Observational

103

Málaga, Palma, Badalona, Santander, Cartagena, Gijón, Seville, Almería

2025-11-17

Recruiting

Precision of Pacient-specific Instrumented Open Wedge High Tibial Osteotomy vs Conventional Technicque

NCT07212777Arthritis (Knee), Varus Knee

University of Malaga

Not applicable

Málaga

2025-11-15

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Alicante, Badalona, Granada, Madrid, Manises, Málaga, Santiago de Compostela, Valencia

2025-11-14

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca

2025-11-07

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza

2025-11-05

Recruiting

Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.

NCT07332273Obesity

DrugLevothyroxine

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Phase 3

286

Cadiz, Córdoba, Jaén, Málaga, Valladolid

2025-11-05

Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure

Takeda

Observational

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-03

Not yet open

Implementing Online Mental Health Program

NCT07066943Stress, Healthcare Workers, Mindfulness, Prevention Intervention

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

130

Málaga

2025-11

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

By invitation

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure

Praxis Precision Medicines

Phase 3

700

Barcelona, Madrid, Málaga, Terrassa, Valencia

2025-10-27

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville

2025-10-24

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga

2025-10-24

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Barcelona, Madrid, Málaga, Salamanca, Valencia

2025-10-23

Recruiting

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

NCT07168434IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms

DrugSaccharomyces Boulardii

Biocodex

Phase 3

406

Barcelona, León, Madrid, Marbella, Málaga, Oviedo

2025-10-22

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo

2025-10-22

Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor

Zymeworks BC Inc.

Phase 1

140

Barcelona, Logroño, Madrid, Málaga, Pamplona

2025-10-21

Not yet open

Effects Obtained at Manual Function After Applying Anodic Transcranial Direct Current Stimulation (tCDS) in Children With Spastic Hemiparetic Cerebral Palsy

NCT06438666Hemiparetic Cerebral Palsy

University of Malaga

Not applicable

Málaga

2025-10-20

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Barcelona, Málaga, Palma de Mallorca

2025-10-20

Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725Solid Tumours

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

540

Málaga, Badalona, Barcelona, Pamplona, Madrid

2025-10-15

Recruiting

Chronobiology and Enteral Nutrition

NCT07554716Hospitalised Patients With Enteral Nutrition

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2025-10-10

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab·Visugromab RDE·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Jaén, Málaga, Seville, Barcelona, Santiago de Compostela, Girona, Logroño, Madrid

2025-10-07

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Barcelona, Madrid, Oviedo, Málaga

2025-10-03

By invitation

Central Sensitization Syndromes and Post-Traumatic Stress in Women: Psychological Profile and Intervention

NCT07313280Posttraumatic Stress Symptom, Central Sensitization, Chronic Pain Syndrome

University of Malaga

Not applicable

Málaga

2025-10-02

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2025-10-01

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid

2025-09-22

Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive

DrugGilteritinib

Astellas Pharma Global Development, Inc.

Phase 1

Barcelona, Madrid, Málaga

2025-09-22

Recruiting

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.

Phase 2

240

Alicante, Barcelona, Málaga, Valencia

2025-09-17

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Mérida, L'Hospitalet de Llobregat, Jerez de la Frontera, Benalmádena, Cáceres, Málaga, Palma, Seville

2025-09-16

Active, closed

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06992609Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander

2025-09-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid

2025-09-15

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

A Coruña, Elche, Barcelona, Hospitalet, Donostia / San Sebastian, Madrid, Málaga, Valencia

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

A Coruña, Barcelona, Cadiz, Castellon, Ferrol, Jerez de la Frontera, Madrid, Málaga

2025-09-10

Recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07039110Plaque Psoriasis

AbbVie

Observational

700

Málaga, León, Cartagena, El Palmar, Murcia, Pontevedra, Toledo

2025-09-09

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Barcelona, Hospitalet, Madrid, Málaga, Seville, Valencia

2025-09-09

Recruiting

Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest

NCT07174986Out of Hospital Cardiac Arrest, Ventricular Fibrillation, Defibrillation, CPR

Gabriel Riva

Phase 2/3

916

Málaga, Bilbao, Barcelona, Madrid

2025-09-08

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville

2025-09-08

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Barcelona, Jerez de la Frontera, Madrid, Málaga

2025-09-02

Recruiting

Efficacy of Early Multimodal Physiotherapy in Patients With Reverse Shoulder Prosthesis

NCT06357143Shoulder Fractures, Prosthesis User

University of Malaga

Not applicable

Málaga

2025-09-01

Recruiting

Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy

NCT07678112Rheumatoid Arthritis (RA)

Francisco J. Blanco

Not applicable

184

A Coruña, Alava, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna

2025-08-28

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Almería, Barcelona, Madrid, Málaga, Santander, Vigo

2025-08-27

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700Episodic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

990

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713Chronic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

780

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Seville, Santander, Castilleja de la Cuesta, A Coruña, Ferrol, Malaga, Málaga, Barcelona

2025-08-19

Active, closed

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin

Amgen

Phase 3

350

Málaga, Barcelona, Majadahonda, Valencia, Madrid

2025-08-18

Recruiting

Chronobiology and Home Parenteral Nutrition Study. CHRONO-HPN Study

NCT07554703Patients With Home Parenteral Nutrition

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2025-08-18

Recruiting

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054Pancreatic Adenocarcinoma

DrugSotorasib

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 1

Zaragoza, Barcelona, Santander, Córdoba, Donostia / San Sebastian, Madrid, Málaga, Pamplona

2025-08-08

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

A Coruña, Madrid, Manresa, Málaga, Santander, Valencia

2025-08-07

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander

2025-08-06

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Zaragoza

2025-08-05

Active, closed

Footwear and Brain Activity in Children

NCT07151352Foot, Footwear, Children

University of Malaga

Not applicable

Málaga

2025-08-01

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo

2025-08-01

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja

2025-08-01

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Castilleja de la Cuesta, Córdoba, Jaén, Málaga, Seville, San Cristóbal de La Laguna, Santander, Badalona

2025-07-25

Active, closed

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503Asthma (Diagnosis)

DrugWIN378

Windward Bio

Phase 2

136

Chiclana de la Frontera, Madrid, San Sebastián, Pozuelo de Alarcón, Benalmádena, Málaga, Seville

2025-07-24

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia

2025-07-17

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville

2025-07-17

Active, closed

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Barcelona, Esplugues de Llobregat, Donostia / San Sebastian, Madrid, Málaga, Murcia

2025-07-14

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-07-10

Recruiting

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

NCT07362654Celiac Disease, Gluten Sensitivity, Autoimmune Diseases

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2025-07-07

Recruiting

NIMA-Colon Cancer Study

NCT07534852Colon Cancer

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

120

Málaga

2025-07-01

Active, closed

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453Breast Cancer, Breast Neoplasms

DrugDisitamab Vedotin

Pfizer

Phase 1/2

Barcelona, Madrid, Málaga, Valencia, Granada

2025-06-30

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Benalmádena, Granollers, Madrid, Málaga, Mérida, Pozuelo de Alarcón, Santander

2025-06-27

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña

2025-06-25

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Barcelona, Madrid, Málaga, Santiago de Compostela

2025-06-24

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-06-23

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela

2025-06-17

Recruiting

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

NCT06990880Neoplasms, Prostate

GlaxoSmithKline

Phase 1/2

Badajoz, Barcelona, Madrid, Málaga, Pozuelo de AlarcOn Madr

2025-06-12

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia

2025-06-05

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia

2025-06-04

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-06-04

Active, closed

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C

DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir

Atea Pharmaceuticals, Inc.

Phase 3

880

Santander, Málaga, Vigo, Barcelona

2025-06-02

Not yet open

Endophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy

NCT06997432Food Allergies

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Observational

Málaga

2025-06

Recruiting

Optimize Risk Prediction After Myocardial Infarction: The ORACLE Study

NCT06993415Myocardial Infarction (MI)

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Observational

750

Málaga

2025-06

Recruiting

Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study

NCT06852014Pancreatic Cancer, Adult, Cephalic Duodenopancreatectomy

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2025-05-29

Active, closed

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Blueprint Medicines Corporation

Phase 2

105

Barcelona, Málaga

2025-05-28

Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck

DrugPembrolizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

200

Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-23

Active, closed

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830Hemophilia A

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

252

Salamanca, A Coruña, Barcelona, Málaga, Palma de Mallorca, Zaragoza

2025-05-21

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Santander, Madrid, Pozuelo de Alarcón, Málaga

2025-05-20

Recruiting

The Cooling Sensation Safe Deglution Study

NCT06936501Neuromotor Dysphagia After Acute Stroke

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2025-05-19

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Badajoz, Barakaldo, Barcelona, Cadiz, Córdoba, Granada, Madrid, Málaga

2025-05-19

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia

2025-05-15

Recruiting

FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

NCT06968364Threatened Preterm Labor

Ultrasound-Innovation Medtech, S.L.

Not applicable

457

A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-10

Active, closed

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity

DrugsRO7204239·Tirzepatide

Hoffmann-La Roche

Phase 2

285

Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga

2025-05-05

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Barcelona, Córdoba, Málaga, Seville, Torrejón de Ardoz, Valencia

2025-05-02

Recruiting

Optimising TREATment for Severe Gram-Negative Bacterial Infections

NCT07004049Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection

DrugsCeftolozane-tazobactam·Cefiderocol·Fosfomycin·Meropenem-Vaborbactam

National University of Singapore

Phase 4

600

Alicante, Badajoz, Barakaldo, Barcelona, Córdoba, Granada, Madrid, Málaga

2025-04-21

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Granada, Barcelona, Santander, Madrid, Málaga

2025-04-17

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

L'Hospitalet de Llobregat, Majadhonda, Madrid, Valencia, Barcelona, Málaga

2025-04-15

Recruiting

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

NCT06943469Atopic Dermatitis (AD)

Société des Produits Nestlé (SPN)

Not applicable

400

A Coruña, Almería, Barcelona, Madrid, Málaga, Seville, Tarragona, Zaragoza

2025-04-10

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville

2025-04-09

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Barcelona, Madrid, Málaga, Pamplona, Seville

2025-04-09

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

A Coruña, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Málaga, Seville

2025-04-04

By invitation

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

300

Barcelona, Majadahonda, Pamplona, Málaga, Valencia

2025-04-01

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma

2025-03-27

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona

2025-03-27

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Barcelona, Madrid, Málaga, Mérida, Patraix, Santander

2025-03-26

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga

2025-03-25

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128MTAP-deleted Solid Tumors

Bayer

Phase 1/2

450

Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Málaga, Valencia, Pamplona

2025-03-21

Active, closed

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsEfti·Pemetrexed·Keytruda·Paclitaxel

Immutep S.A.S.

Phase 3

756

Badalona, Barcelona, Córdoba, Madrid, Málaga, Oviedo, Sabadell, Seville

2025-03-21

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville

2025-03-18

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Sant Joan Despí, Santiago(A Coruña)

2025-03-14

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia

2025-03-12

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Santander, Seville, A Coruña, Alicante, Barcelona, Málaga

2025-03-06

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

A Coruña, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2025-03-04

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Mérida, Sabadell, Santiago de Compostela, Málaga, Seville, Valencia

2025-03-03

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Majadahonda, Málaga, Palma deMallorca, Pamplona

2025-03-03

Recruiting

Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).

NCT07247669Chest Pain, Stroke Acute, Respiratory Failure, Cardiac Arrest (CA)

Centro de Emergencias Sanitarias 061 Andalucía

Observational

5,000,000

Málaga

2025-03-01

Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

DrugsMomelotinib·Reblozyl·Luspatercept

GlaxoSmithKline

Phase 2

Badalona, Barcelona, Las Palmas, Madrid, Málaga, Valencia

2025-02-28

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Eixample, L'Hospitalet de Llobregat, Madrid, Barcelona, Málaga

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia

2025-02-27

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville

2025-02-21

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Badalona, Pamplona, Burjassot, Madrid, Málaga

2025-02-19

Recruiting

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

NCT06828848Gram Negative Infections

DrugMeropenem

Menarini Group

Phase 2

Barcelona, Cadiz, Girona, Madrid, Málaga, Santiago de Compostela

2025-02-18

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2025-02-12

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville

2025-02-10

Active, closed

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

180

Barcelona, Lleida, Madrid, Málaga, Valencia

2025-02-07

By invitation

Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies.

NCT06363526Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Muscular Dystrophy

University of Malaga

Not applicable

Málaga

2025-02-05

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Barcelona, Madrid, Málaga

2025-02-05

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville

2025-02-04

Recruiting

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

NCT06897839Bronchopulmonary Dysplasia

Airway Therapeutics, Inc.

Phase 2/3

366

Alicante, Barcelona, Bilbao, Cadiz, Lleida, Madrid, Málaga, Santiago de Compostela

2025-02-03

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Badajoz, Barcelona, Castellon, León, Madrid, Málaga, Seville, Torrejón de Ardoz

2025-02-03

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Málaga, Lorca, Vigo, Seville, Granada, Huelva, Madrid, Murcia

2025-01-31

Active, closed

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

NCT06612203Advanced Breast Cancer

DrugSacituzumab Govitecan

MedSIR

Phase 1/2

Barcelona, Granada, Madrid, Málaga, Valencia

2025-01-17

Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer

DrugZanidatamab

Jazz Pharmaceuticals

Phase 2

200

Málaga

2025-01-14

Active, closed

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

Amgen

Phase 3

152

Alcorcón, Barcelona, Castilleja de la Cuesta, DÃ©nia, Madrid, Malag, Málaga, Salt

2025-01-13

Recruiting

Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients

NCT06558526Food Allergy

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2025-01-13

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

NCT06754462Rheumatoid Arthritis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

120

Barcelona, Bilbao, Málaga, Seville

2025-01-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Active, closed

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors

DrugR-DXd

Daiichi Sankyo

Phase 2

335

A Coruña, Barcelona, Madrid, Málaga

2025-01-06

Active, closed

Prehospital Emergency Airway Research.

NCT07289139Airway Management, Emergency

Centro de Emergencias Sanitarias 061 Andalucía

Observational

4,300

Málaga

2025-01-01

Active, closed

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369Non Squamous Non Small Cell Lung Cancer

DrugsEU sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin

mAbxience Research S.L.

Phase 3

726

A Coruña, Barcelona, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra

2024-12-30

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga

2024-12-24

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

NCT06637423Non-Muscle Invasive Bladder Cancer

DrugSacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

Málaga, Madrid

2024-12-20

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Alicante, Badalona, Barcelona, Madrid, Málaga, San Sebastián

2024-12-18

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-12-17

Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma

Alentis Therapeutics AG

Phase 1/2

170

PAU de Sanchinarro, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville, Valencia

2024-12-16

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander

2024-12-16

Recruiting

Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

NCT06724159Genitourinary Cancers

DrugsEnfortumab Vedotin·Darolutamide·Nivolumab

Spanish Oncology Genito-Urinary Group

Observational

500

Albacete, Alicante, Almería, Córdoba, Granada, Jaén, Jerez de la Frontera, Málaga

2024-12-13

Active, closed

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer

GlaxoSmithKline

Phase 1/2

Barcelona, Madrid, Málaga

2024-12-13

Active, closed

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

NCT06675864Progressive Multiple Sclerosis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid, Málaga

2024-12-12

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Badajoz, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia

2024-12-12

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville

2024-12-09

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid

2024-12-09

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

Málaga, L'Hospitalet de Llobregat, Madrid

2024-12-09

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia

2024-12-05

Recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor

DrugNiraparib

MedSIR

Phase 2

A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo

2024-12-03

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga

2024-12-03

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·B/F/TAF·Cabotegravir

ViiV Healthcare

Phase 3

326

L'Hospitalet de Llobregat, Bilbao, Puerto Real, Barcelona, Córdoba, Madrid, Málaga, Murcia

2024-12-02

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Málaga, L'Hospitalet de Llobregat, Leganés, Majadahonda, Oviedo, Seville, Barcelona, Madrid

2024-11-26

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

Logroño, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-11-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

A Coruña, Badajoz, Barcelona, Castellon, Madrid, Málaga, Mérida, Sabadell

2024-11-21

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz

2024-11-18

Active, closed

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

NCT06415175Atopic Dermatitis

DrugDupilumab

Sanofi

Observational

143

Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga

2024-11-14

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Barcelona, Madrid, Málaga, Seville, Valencia

2024-11-14

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2024-11-11

Recruiting

Effectiveness of Inspiratory Muscle Training for People With Ischemic Heart Disease Revascularized by Percutaneous Transluminal Coronary Angioplasty.

NCT06681740Myocardial Ischemia, Coronary Arterial Disease (CAD)

University of Cadiz

Not applicable

Málaga

2024-11-11

Active, closed

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173Type 2 Diabetes Mellitus (T2DM)

DrugMaridebart cafraglutide

Amgen

Phase 2

409

Castilleja de la Cuesta, Málaga, Lleida, A Coruña, Alzira

2024-11-07

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga

2024-11-07

Recruiting

Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)

NCT06698159Atrial Fibrillation, Atrial Fibrillation (Paroxysmal)

Hospital Universitario 12 de Octubre

Not applicable

440

Bilbao, Granada, Huelva, Madrid, Málaga, Seville

2024-11-01

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-10-29

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

NCT06651567Agitation Associated With Alzheimer's Dementia

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

320

Albacete, Badalona, Málaga, Zamora, Zaragoza

2024-10-22

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Canarias, A Coruña, Pozuelo de Alarcón, Barcelona, Madrid, Málaga

2024-10-21

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Barcelona, Madrid, Málaga

2024-10-21

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

A Coruña, Alcobendas, Bilbao, Castelló, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander

2024-10-11

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

A Coruña, Barcelona, Málaga

2024-10-09

Recruiting

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

NCT06423898Endocarditis, Infective

DrugAmpicillin

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 4

284

Alava, Barakaldo, Barcelona, Donostia / San Sebastian, Granada, Logroño, Madrid, Málaga

2024-10-09

Recruiting

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

200

Málaga, Valencia, Barcelona, Madrid, Salamanca

2024-10-09

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

A Coruña, Barcelona, L'Hospitalet de Llobregat, Palma, Madrid, Majadahonda, Valencia, Málaga

2024-10-07

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

Málaga, Barcelona, Valencia, Madrid

2024-10-07

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-10-04

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Badajoz, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-30

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Majadahonda, Málaga, Lleida, Madrid, Salamanca, Seville, Valladolid, Zaragoza

2024-09-26

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga

2024-09-25

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-23

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Granada, Málaga, Palma, Badalona, Barcelona, El Palmar, Oviedo, Madrid

2024-09-18

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville

2024-09-11

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

Alicante, Barcelona, Jaén, Madrid, Mataró, Málaga, Oviedo, Seville

2024-09-09

Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06544785Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsZanubrutinib Product·Zanubrutinib·Obinutuzumab

PETHEMA Foundation

Phase 2

106

Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Marbella, Málaga, Oviedo

2024-09-02

Active, closed

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

UroGen Pharma Ltd.

Phase 3

Málaga, Barcelona, Madrid

2024-08-29

Active, closed

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772Coeliac Disease, Celiac Disease

DrugAmlitelimab

Sanofi

Phase 2

229

Barcelona, Chiclana de la Frontera, Las Palmas de Gran Canaria, Seville, Madrid, Málaga

2024-08-29

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

A Coruña, Barcelona, Jaén, Madrid, Málaga, Palma, Sabadell, San Sebastián

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Madrid, Málaga, Murcia, Seville, Valencia

2024-08-26

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Santiago de Compostela, Barcelona, Majadahonda, Pamplona, Málaga, Sabadell, Santa Cruz de Tenerife, Valencia

2024-08-21

Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950Heart Failure

DrugFinerenone

Colorado Prevention Center

Phase 3

2,600

Girona, A Coruña, Santiago de Compostela, Madrid, Majadahonda, Málaga, Manises, Valencia

2024-08-20

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Barcelona, Madrid, Málaga, Santander

2024-08-12

Recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

110

Ferrol, Esplugues de Llobregat, Málaga, Seville, Zaragoza

2024-08-08

Active, closed

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572Non-small Cell Lung Cancer (NSCLC)

DrugsS095029·Cemiplimab

Servier Bio-Innovation LLC

Phase 1/2

102

Barcelona, Madrid, Málaga, Valencia

2024-08-07

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Málaga, Centelles, Barcelona, Figueres, A Coruña, Santiago de Compostela, Pozuelo de Alarcón, Alcorcón

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Not yet open

Lymphatic Response to Resistance Exercise in Breast Cancer Survivors

NCT06113627Breast Cancer Lymphedema, Survivorship, Lymphedema of Upper Limb

University of Malaga

Not applicable

170

Málaga

2024-08

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia

2024-07-31

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

Elche, Seville, Barcelona, Torrejón de Ardoz, Lleida, Madrid, Málaga, Pamplona

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Recruiting

PulseSelect™ PFA Global Registry

NCT06393920Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

1,950

Córdoba, Málaga, Salamanca

2024-07-23

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo

2024-07-22

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Recruiting

The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer

NCT06643065Vaginal Microbiome

Fundación IVI

Observational

1,573

Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza

2024-07-17

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Córdoba, Granada, Málaga, Seville, Zaragoza, Santander, Burgos, Badalona

2024-07-17

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746Heart Failure

DrugsFinerenone·Dapagliflozin

Colorado Prevention Center

Phase 3

1,500

A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona

2024-07-09

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Badalona, Barcelona, Sabadell, Santander, Cadiz, Madrid, Málaga, Barakaldo

2024-07-05

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Sabadell, Santander, Manises, Madrid, Málaga, Valencia

2024-06-27

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Badalona, Málaga, El Palmar, A Coruña, Alicante, Barcelona, Lleida, Madrid

2024-06-25

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela

2024-06-17

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville

2024-06-10

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia

2024-06-03

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306Solid Tumor, Adult

DrugsKQB198·Tagrisso·Amivantamab·Osimertinib

Kumquat Biosciences Inc.

Phase 1

Barcelona, Madrid, Málaga, Pamplona

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Barcelona, Córdoba, Madrid, Málaga, Valencia

2024-06-03

Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464Prader-Willi Syndrome

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

134

Barcelona, Madrid, Málaga

2024-05-28

Recruiting

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

NCT05993442Infection, Bacterial, Infection Prevention

PENTA Foundation

Not applicable

3,080

Alicante, Bilbao, Málaga

2024-05-28

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Almería, Badalona, Barcelona, Córdoba, Madrid, Málaga, Pontevedra, Santander

2024-05-24

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville

2024-05-24

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga

2024-05-21

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

A Coruña, Almería, Alzira, Barcelona, Ferrol, Málaga, Oviedo, Palma de Mallorca

2024-04-30

Recruiting

Mentalizing and Epistemic Trust in Patients With Anxiety and Depression.

NCT06833567Anxiety Disorders, Depression

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

100

Málaga

2024-04-28

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

A Coruña, Alzira, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Málaga

2024-04-18

Recruiting

Integrated Approach in Frail Older People with Atrial Fibrillation

NCT06775028Atrial Fibrillation (AF), Hypertension, Coronary Arterial Disease (CAD), Heart Failure

Heart Care Foundation

Not applicable

1,250

Alicante, Cartagena, Cártama, Elche, Málaga, Murcia, Sant Joan d'Alacant, Tarragona

2024-04-11

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia

2024-04-09

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz

2024-04-03

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

A Coruña, Alcalá de Henares, Lleida, Madrid, Málaga, Murcia, Oviedo, Seville

2024-03-29

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Palma deMallorca

2024-03-29

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672Polycythemia Vera

DrugHydroxyurea

Italfarmaco

Phase 3

220

Badalona, Alicante, Madrid, Málaga, Valencia

2024-03-26

Recruiting

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer

Voronoi, Inc

Phase 1/2

315

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga

2024-03-26

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer

Iambic Therapeutics, Inc

Phase 1

383

Barcelona, Madrid, Málaga, Seville, Valencia

2024-03-25

Recruiting

Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?

NCT06582342Adenocarcinoma of the Pancreas

Fundación para la Investigación del Hospital Clínico de Valencia

Observational

Alicante, Badajoz, Barcelona, Candelaria, Castellon, Málaga, Murcia, Palma de Mallorca

2024-03-21

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pontevedra, Santander, Santiago de Compostela

2024-03-13

Active, closed

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

NCT06348199Non-small Cell Lung Cancer Stage IV

DrugsKeytruda·Pembrolizumab

Samsung Bioepis Co., Ltd.

Phase 3

555

Leganés, Málaga, Ourense, Oviedo, Santiago de Compostela, Seville, Valencia

2024-03-12

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT05935215Atypical Hemolytic Uremic Syndrome

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia

2024-02-28

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Barcelona, Madrid, Málaga, Seville, Valencia

2024-02-26

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Palma, A Coruña, Barcelona, Alicante, Badalona, Castellon, Madrid, Málaga

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda

2024-02-20

Active, closed

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140Carcinoma, Non-Small-Cell Lung

DrugsClobetasol·Minocycline·Chlorhexidine·Clindamycin

Janssen Research & Development, LLC

Phase 2

305

A Coruña, Alicante, Barcelona, Jaén, Lugo, Madrid, Málaga, Seville

2024-02-16

By invitation

Efficacy of Hyaluronic Acid Cream in Preventing Foot Ulceration Risk in Patients With Type 2 Diabetes and Moderate-to-Severe Peripheral Neuropathy: A Randomized Clinical Trial.

NCT07131410DIABETES

University of Malaga

Not applicable

Málaga

2024-02-15

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia

2024-02-09

Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase

DrugsBosutinib·Olverembatinib

Ascentage Pharma Group Inc.

Phase 3

333

Badalona, Barcelona, Elche, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Murcia

2024-02-05

Active, closed

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

200

Santiago de Compostela, Málaga, Palma de Mallorca, Oviedo, Barcelona, Madrid, Seville, Valencia

2024-02-01

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia

2024-01-23

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

Barcelona, Madrid, Seville, Valencia, Málaga, Pozuelo de Alarcón

2024-01-23

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Barcelona, Sant Cugat del Vallès, Santiago de Compostela, Madrid, Majadahonda, Pozuelo de Alarcón, Málaga, Pamplona

2024-01-18

Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed

Revolution Medicines, Inc.

Phase 1/2

616

Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville

2024-01-18

Active, closed

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

NCT06268613Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA

DrugsEU sourced Keytruda·US-sourced Keytruda·Pembrolizumab

Samsung Bioepis Co., Ltd.

Phase 1

163

Jaén, A Coruña, Málaga

2024-01-16

Active, closed

International Non-selection Study for ERA® Test in Patients With Previous Implantation Failures

NCT06097559Infertility of Uterine Origin, Implantation Failure

Igenomix

Observational

738

Madrid, Marbella, Málaga, Seville, Valladolid

2024-01-16

Recruiting

Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter Stents

NCT06201598Cerebral Aneurysm, Thromboembolic Disease

Hospital Universitario Central de Asturias

Observational

100

A Coruña, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Madrid, Málaga, Oviedo

2024-01-12

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-01-11

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Alicante, Badalona, Barcelona, Cadiz, Madrid, Málaga, Santander, Valencia

2024-01-11

Recruiting

Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.

NCT06270199Bronchopulmonary Dysplasia

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 2

Pozuelo de Alarcón, A Coruña, Madrid, Málaga, Seville, Valencia

2024-01-11

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263Acute Myeloid Leukemia

DrugsRVU120·Venetoclax

Ryvu Therapeutics SA

Phase 2

Barcelona, Cáceres, Madrid, Málaga, Pamplona, Seville, Valencia

2024-01-05

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga

2023-12-31

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Málaga, Barcelona, Madrid, Pamplona, Salamanca

2023-12-29

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia

2023-12-21

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Sabadell, Barcelona, Girona, A Coruña, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Burgos, Málaga

2023-12-18

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Ávila, Granada, Madrid, Málaga, Valencia, Vigo

2023-12-18

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Barcelona, A Coruña, Madrid, Málaga, Jaén

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Jerez de la Frontera, A Coruña, Pozuelo de Alarcón, Málaga, Valencia, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-15

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

A Coruña, Barcelona, Majadahonda, Málaga, Palma de Mallorca

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón

2023-12-12

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

110

Ferrol, Madrid, Málaga

2023-12-11

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Barcelona, Esplugues de Llobregat, Oviedo, Seville, Málaga, Valencia, Vitoria-Gasteiz

2023-12-11

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

L'Hospitalet de Llobregat, Pozuelo de Alarcón, Majadahonda, Málaga, Barcelona, Seville

2023-12-06

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander

2023-12-04

Recruiting

The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study

NCT05847387Corneal Transplant Failure, Corneal Endothelial Cell Loss

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Observational

135

Málaga

2023-12-01

Active, closed

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06173531Hyperphagia in Prader-Willi Syndrome

DrugCarbetocin

ACADIA Pharmaceuticals Inc.

Phase 3

170

Barcelona, Madrid, Málaga

2023-11-27

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsLumakras·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona

2023-11-16

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Madrid, Pamplona, Barcelona, Málaga, Murcia, Valencia

2023-11-13

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Espluges de Llobregat, Horcajo de la Sierra, Málaga, Barcelona, Madrid

2023-11-13

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Barcelona, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Madrid, Málaga

2023-11-12

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma

DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab

AbbVie

Phase 1

325

Badalona, Pamplona, Barcelona, Madrid, Málaga, Zaragoza

2023-11-09

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

A Coruña, Barcelona, Madrid, Málaga, Valencia

2023-11-08

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

L'Hospitalet de Llobregat, Majadahonda, El Palmar, Madrid, Málaga, Seville, Valencia

2023-11-07

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Ferrol, Esplugues de Llobregat, Barcelona, Málaga

2023-11-06

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia

2023-11-02

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia

2023-10-31

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Badalona, Barcelona, Santander, Santiago de Compostela, Málaga, Madrid, Majadahonda, Oviedo

2023-10-25

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Alicante, Barcelona, Bilbao (Vizcaya), Madrid, Málaga, Palma

2023-10-24

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

Badalona, Málaga, Pamplona/iruña, Oviedo, Barcelona, Madrid

2023-10-18

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

DrugObrixtamig

Boehringer Ingelheim

Phase 2

204

Barcelona, Madrid, Málaga, Valencia

2023-10-13

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444Chronic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

759

Madrid, Málaga, Seville, Valencia

2023-10-12

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Torrevieja, Córdoba, Málaga, Seville, Calella, Barcelona, Centelles, L'Hospitalet de Llobregat

2023-10-09

Active, closed

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

NCT05888844Cutaneous Squamous Cell Carcinoma

DrugINCB099280

Incyte Corporation

Phase 2

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville

2023-10-09

Recruiting

Post-Market Clinical Follow Up Study With Navitor Valve

NCT06008080Aortic Stenosis

Abbott Medical Devices

Observational

1,000

Badajoz, Barcelona, Huelva, Las Palmas, Majadahonda, Málaga, Valencia

2023-09-29

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

751

Barcelona, Madrid, Málaga, Valencia

2023-09-29

Recruiting

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation

Pierre Fabre Medicament

Phase 1/2

345

Logroño, Málaga, Barcelona, Madrid, Seville

2023-09-26

Active, closed

MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect

NCT05816122Multiple Sclerosis

Ad scientiam

Not applicable

336

Girona, Madrid, Málaga, Oviedo, Zaragoza

2023-09-22

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449Hemophilia A

Hoffmann-La Roche

Phase 1/2

Esplugues de Llobregat, Madrid, Málaga

2023-09-21

Active, closed

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis

DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

270

Barcelona, Santander, Córdoba, Málaga

2023-09-13

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

A Coruña, Barcelona, Madrid, Málaga, Seville

2023-09-08

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Barcelona, Lleida, Madrid, Málaga

2023-09-07

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville

2023-09-07

Active, closed

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

NCT06059001Metastatic Pancreatic Cancer

DrugsOMO-103·Nab-paclitaxel·Gemcitabine

Peptomyc S.L.

Phase 1

Barcelona, L'Hospitalet de Llobregat, Santander, Madrid, Málaga, Zaragoza

2023-08-31

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Barcelona, Madrid, Majadahonda, Málaga, Pontevedra, Sabadell, Seville, Valencia

2023-08-31

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Salamanca, Seville

2023-08-31

Recruiting

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor

Daiichi Sankyo

Phase 1/2

590

Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville

2023-08-18

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615Hormone-refractory Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 1

437

Barcelona, Logroño, Madrid, Málaga, Pamplona, Valencia

2023-08-10

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Badalona, Barcelona, Jaén, Málaga, Granada, Madrid

2023-08-09

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

DrugZipalertinib

Taiho Oncology, Inc.

Phase 2

220

Málaga, Barcelona, Jaén, Madrid

2023-07-31

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Barcelona, Pozuelo de Alarcón, Madrid, Málaga, Valencia

2023-07-19

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Majadahonda, Málaga, Barcelona, Lleida, Madrid, Salamanca, Seville, Valladolid

2023-07-11

Recruiting

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

NCT05999877Chronic Lymphocytic Leukemia

AstraZeneca

Observational

315

Almería, Córdoba, Granada, Jaén, Marbella, Málaga, Seville, Zaragoza

2023-07-11

Recruiting

Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System

NCT04861805Symptomatic Aortic Stenosis

P+F Products + Features GmbH

Not applicable

267

Barcelona, Madrid, Valladolid, Majadahonda, Málaga, Oviedo

2023-07-03

Active, closed

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767Advanced Non-Small Cell Lung Cancer

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2/3

149

Santiago de Compostela, Palma, Barcelona, Majadahonda, Oviedo, Madrid, Málaga, Seville

2023-06-30

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Elche, Lugo, Madrid, Málaga, Valencia

2023-06-28

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

L'Hospitalet de Llobregat, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Cáceres, Madrid, Málaga, Murcia

2023-06-07

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

Málaga, Badalona, Pamplona, Madrid

2023-06-06

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Barcelona, Madrid, Málaga

2023-06-05

Active, closed

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903Obesity, Overweight, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

3,127

A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid

2023-06-05

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Málaga, A Coruña, Barcelona, Madrid, Valencia

2023-06-01

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Málaga, Zaragoza, Barcelona, A Coruña, Majadahonda, Madrid

2023-05-31

Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831Locally Advanced Solid Tumor

DrugsTNG462·Keytruda·Pembrolizumab

Tango Therapeutics, Inc.

Phase 1/2

225

Barcelona, Madrid, Málaga, Seville

2023-05-26

Recruiting

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

NCT06923761Advanced Solid Malignancy

Grey Wolf Therapeutics

Phase 1/2

300

Barcelona, Madrid, Málaga, Pamplona, Valencia

2023-05-21

Active, closed

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Carcinoma, Non-Small-Cell Lung

DrugsMontelukast·Lazertinib·Amivantamab·Methotrexate

Janssen Research & Development, LLC

Phase 2

Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Málaga, Palma de Mallorca, Santiago de Compostela

2023-05-18

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

Sagunto, Barcelona, Madrid, Málaga, Seville

2023-05-16

Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

NCT05562466Asthma

DrugBudesonide

Novartis Pharmaceuticals

Phase 3

200

Esplugues, Sabadell, Barcelona, Córdoba, Madrid, Málaga

2023-05-11

Recruiting

Effectiveness and Implementation of a Digital Intervention for Pediatric Chronic Pain Co-designed With Patients

NCT05917626Chronic Pain

University of Malaga

Not applicable

195

Almería, Barcelona, Granada, Madrid, Cartagena, Málaga

2023-05-05

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

A Coruña, Barcelona, Las Palmas, Lugo, Madrid, Majadahonda, Málaga, Seville

2023-05-04

Recruiting

Usefulness of PET-CT for Invasive Fungal Infection

NCT05688592Invasive Fungal Infections

Puerta de Hierro University Hospital

Observational

224

Majadahonda, Barcelona, Granada, Madrid, Málaga, Murcia, Oviedo, Salamanca

2023-04-27

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Barakaldo, Barcelona, Madrid, Málaga, Valencia, Valladolid

2023-04-25

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia

2023-04-21

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Majadahonda, Pozuelo de Alarcón, Barcelona, Málaga, Seville, Valencia

2023-04-19

Recruiting

Observational Cross-reactivity Study for Colorectal Cancer Diagnosis

NCT06889844Colorectal Cancer

ADVANCED MARKER DISCOVERY S.L.

Observational

250

Málaga, Oviedo, Ourense, Madrid

2023-04-17

Active, closed

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

NCT07304843Primary Biliary Cholangitis (PBC)

Umecrine Cognition AB

Phase 1/2

202

Barcelona, Madrid, Málaga, Pontevedra, Santander, Seville, Valencia

2023-04-14

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

A Coruña, Alicante, Barcelona, El Palmar, Lleida, Madrid, Manises, Málaga

2023-04-11

Active, closed

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

NCT05758909Aortic Valve Disease, Aortic Valve Stenosis, Heart Valve Diseases

Fundación EPIC

Observational

585

A Coruña, Alicante, Aravaca, Badalona, Barcelona, L'Hospitalet de Llobregat, Málaga, Oviedo

2023-04-04

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Santiago de Compostela, Santander, Barcelona, Cadiz, Madrid, Málaga, Murcia, Seville

2023-04-03

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia

2023-03-30

Recruiting

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

NCT05692999Metastatic Non-squamous Lung Cancer

DrugsPemetrexed /m^2·Pembrolizumab

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

1,166

Barcelona, Madrid, Málaga, Seville

2023-03-20

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid

2023-03-15

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Ferrol, Santiago, Santiago Compostela, Elche, Granada, Huelva, Marbella, Málaga

2023-03-09

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

Elche, Badalona, Barcelona, L'Hospitalet de Llobregat,Barcelona, Madrid, Málaga

2023-03-08

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Barcelona, Málaga, Santander, Seville

2023-03-06

Active, closed

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

NCT05741476Allergy, Peanut

DBV Technologies

Phase 3

600

Madrid, Málaga

2023-02-21

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Barcelona, Las Palmas de Gran Canaria, Lugo, Málaga, Seville, Valencia

2023-02-21

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Madrid, Málaga, Valladolid, Valparaíso

2023-02-14

Active, closed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238Haemophilia A, Haemophilia A With Inhibitors

Novo Nordisk A/S

Phase 3

451

Barcelona, Esplugues Llobregat, Madrid, Málaga

2023-02-13

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

A Coruña, Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Valencia

2023-01-24

Active, closed

Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant

NCT05186857Graft-versus-host Disease

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Observational

Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia

2023-01-23

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valenica, Zaragoza

2023-01-11

Active, closed

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

DrugGSK4532990

GlaxoSmithKline

Phase 2

284

Barcelona, Madrid, Málaga, Sabadell Barcelona, Santander, Seville, Vigo

2023-01-02

Recruiting

The Role of Breast Milk Neutrophils From Mothers With Metabolic Diseases After Nutritional Intervention. Impact on Infant Development and Response to Pulmonary Infections

NCT06833554Gestational Diabetes Mellitus (GDM)

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Not applicable

Málaga

2023-01-01

Active, closed

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673Non-Clear Cell Renal Cell Carcinoma

DrugsSunitinib Malate·Zanzalintinib·Sunitinib·Opdivo

Exelixis

Phase 3

317

Palma de Mallorca, Majadahonda, Barcelona, Córdoba, Girona, Madrid, Málaga, Oviedo

2023-01-01

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Barcelona, Valencia, Bilbao, Córdoba, Granada, Madrid, Málaga

2022-12-29

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)

OSE Immunotherapeutics

Phase 1/2

A Coruña, Girona, Málaga

2022-12-20

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Barcelona, Madrid, Málaga, Valencia

2022-12-19

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat

2022-12-14

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Barcelona, A Coruña, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia

2022-12-13

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander

2022-12-13

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

A Coruña, Badalona, Barcelona, Córdoba, Jaén, Madrid, Málaga, Sabadell

2022-12-13

Active, closed

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT05325593Primary Immune Thrombocytopenia

DrugsRomiplostim·Dexamethasone

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

129

Barcelona, Burgos, A Coruña, Granada, Madrid, Murcia, Málaga, Salamanca

2022-12-02

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia

2022-11-28

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Badalona (Barcelona), Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2022-11-21

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Barcelona, Madrid, Málaga, Valencia

2022-11-15

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

A Coruña, Alicante, Barcelona, Madrid, Málaga, Seville, Valencia

2022-11-11

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville

2022-11-08

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga

2022-10-27

Recruiting

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

NCT05363319Non-small Cell Lung Cancer

DrugCemiplimab

Regeneron Pharmaceuticals

Observational

500

Málaga, Sabadell, Jerez de la Frontera, Castellon, Ferrol, Vigo, Almería, Jaén

2022-10-26

Active, closed

Berotralstat Treatment in Children With Hereditary Angioedema

NCT05453968Hereditary Angioedema, Pediatric

DrugBerotralstat

BioCryst Pharmaceuticals

Phase 3

Madrid, Málaga

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

L'Hospitalet de Llobregat, Barcelona, San Cristóbal de La Laguna, Alicante, Córdoba, Lleida, Madrid, Málaga

2022-10-24

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma

DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab

Genentech, Inc.

Phase 1

165

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2022-10-20

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Badalona, Barcelona, El Palmar, Jerez de la Frontera, León, Madrid, Málaga, Pamplona

2022-10-13

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia

2022-10-04

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/m-laga

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 746 of those studies with a site in Málaga.

How many clinical trials are recruiting in Málaga?

367 of the 746 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 25 have not yet opened recruitment, 339 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Málaga), 746 studies
Phase	Studies	Recruiting	Share
Phase 3	357	155	47.9%
Phase 2	126	55	16.9%
Phase 1/2	71	41	9.5%
Observational	60	41	8%
Not applicable	53	29	7.1%
Phase 1	42	21	5.6%
Phase 2/3	25	18	3.4%
Phase 4	12	7	1.6%

Most active sponsors

Lead sponsors with the most studies (Málaga)
Lead sponsor	Studies	Recruiting
AstraZeneca	66	29
Janssen Research & Development, LLC	30	7
Merck Sharp & Dohme LLC	29	16
Hoffmann-La Roche	28	10
Bristol-Myers Squibb	26	19
Novartis Pharmaceuticals	20	8
GlaxoSmithKline	19	10
Amgen	18	7
Eli Lilly and Company	18	7
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	18	13

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.